Page last updated: 2024-09-04

cilomilast and triazoles

cilomilast has been researched along with triazoles in 2 studies

Compound Research Comparison

Studies (cilomilast)	Trials (cilomilast)	Recent Studies (post-2010) (cilomilast)	Studies (triazoles)	Trials (triazoles)	Recent Studies (post-2010) (triazoles)
162	13	42	25,808	2,252	13,501

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Asaka, N; Kakuo, H; Kiniwa, M; Ohmori, K; Oka, T; Sasaki, E; Togawa, M; Yamada, S	1
Aguiar, JA; Ask, K; Cao, Q; Doxey, AC; Hirota, JA; Hou, V; Huff, RD; Inman, MD; Kim, Y; Miller, MS; Revill, S; Tiessen, N	1

Other Studies

2 other study(ies) available for cilomilast and triazoles

Article	Year
Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets. Arzneimittel-Forschung, 2010, Volume: 60, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Chemotaxis, Leukocyte; Cloning, Molecular; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Ferrets; Guinea Pigs; Humans; Inflammation; Lipopolysaccharides; Male; Nitriles; Phosphodiesterase 4 Inhibitors; Platelet Activating Factor; Rats; Rats, Inbred BN; Rats, Inbred Lew; Respiratory Tract Diseases; Tissue Distribution; Triazoles; Tumor Necrosis Factor-alpha; Vomiting	2010
Potentiation of long-acting β Respiratory research, 2021, Oct-19, Volume: 22, Issue:1 Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Benzothiazoles; Budesonide; Cell Line; Chemokines; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Formoterol Fumarate; Glucocorticoids; Humans; Lung; Multidrug Resistance-Associated Proteins; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Second Messenger Systems; Triazoles	2021

Article

Year

Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.

Arzneimittel-Forschung, 2010, Volume: 60, Issue:9

Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Chemotaxis, Leukocyte; Cloning, Molecular; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Ferrets; Guinea Pigs; Humans; Inflammation; Lipopolysaccharides; Male; Nitriles; Phosphodiesterase 4 Inhibitors; Platelet Activating Factor; Rats; Rats, Inbred BN; Rats, Inbred Lew; Respiratory Tract Diseases; Tissue Distribution; Triazoles; Tumor Necrosis Factor-alpha; Vomiting

2010

Potentiation of long-acting β

Respiratory research, 2021, Oct-19, Volume: 22, Issue:1

Topics: Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Benzothiazoles; Budesonide; Cell Line; Chemokines; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Epithelial Cells; Formoterol Fumarate; Glucocorticoids; Humans; Lung; Multidrug Resistance-Associated Proteins; Nitriles; Phosphodiesterase 4 Inhibitors; Rolipram; Second Messenger Systems; Triazoles

2021